These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 11039761)
1. Potential of gene therapy for treating osteogenesis imperfecta. Niyibizi C; Smith P; Mi Z; Robbins P; Evans C Clin Orthop Relat Res; 2000 Oct; (379 Suppl):S126-33. PubMed ID: 11039761 [TBL] [Abstract][Full Text] [Related]
2. Transfer of proalpha2(I) cDNA into cells of a murine model of human Osteogenesis Imperfecta restores synthesis of type I collagen comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and in vivo. Niyibizi C; Smith P; Mi Z; Phillips CL; Robbins P J Cell Biochem; 2001 Jun 26-Jul 25; 83(1):84-91. PubMed ID: 11500956 [TBL] [Abstract][Full Text] [Related]
3. Gene therapy approaches for osteogenesis imperfecta. Niyibizi C; Wang S; Mi Z; Robbins PD Gene Ther; 2004 Feb; 11(4):408-16. PubMed ID: 14724682 [TBL] [Abstract][Full Text] [Related]
5. Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice. Oestreich AK; Carleton SM; Yao X; Gentry BA; Raw CE; Brown M; Pfeiffer FM; Wang Y; Phillips CL Osteoporos Int; 2016 Jan; 27(1):161-70. PubMed ID: 26179666 [TBL] [Abstract][Full Text] [Related]
6. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Gajko-Galicka A Acta Biochim Pol; 2002; 49(2):433-41. PubMed ID: 12362985 [TBL] [Abstract][Full Text] [Related]
7. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Basel D; Steiner RD Genet Med; 2009 Jun; 11(6):375-85. PubMed ID: 19533842 [TBL] [Abstract][Full Text] [Related]
14. Transgenic mouse model of the mild dominant form of osteogenesis imperfecta. Bonadio J; Saunders TL; Tsai E; Goldstein SA; Morris-Wiman J; Brinkley L; Dolan DF; Altschuler RA; Hawkins JE; Bateman JF Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7145-9. PubMed ID: 2402497 [TBL] [Abstract][Full Text] [Related]
15. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Deyle DR; Khan IF; Ren G; Wang PR; Kho J; Schwarze U; Russell DW Mol Ther; 2012 Jan; 20(1):204-13. PubMed ID: 22031238 [TBL] [Abstract][Full Text] [Related]
16. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects. Pochampally RR; Horwitz EM; DiGirolamo CM; Stokes DS; Prockop DJ Gene Ther; 2005 Jul; 12(14):1119-25. PubMed ID: 15815702 [TBL] [Abstract][Full Text] [Related]
19. Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging. Oyama M; Tatlock A; Fukuta S; Kavalkovich K; Nishimura K; Johnstone B; Robbins PD; Evans CH; Niyibizi C Gene Ther; 1999 Mar; 6(3):321-9. PubMed ID: 10435082 [TBL] [Abstract][Full Text] [Related]
20. Frameshift mutation near the 3' end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I. Willing MC; Cohn DH; Byers PH J Clin Invest; 1990 Jan; 85(1):282-90. PubMed ID: 2295701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]